Advertisement

Topics

Clinical Trials About "NN1250 insulin detemir Diabetes Mellitus Type" RSS

07:33 EDT 17th August 2018 | BioPortfolio

We list hundreds of Clinical Trials about "NN1250 insulin detemir Diabetes Mellitus Type" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "NN1250 insulin detemir Diabetes Mellitus Type" on BioPortfolio

We have published hundreds of NN1250 insulin detemir Diabetes Mellitus Type news stories on BioPortfolio along with dozens of NN1250 insulin detemir Diabetes Mellitus Type Clinical Trials and PubMed Articles about NN1250 insulin detemir Diabetes Mellitus Type for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NN1250 insulin detemir Diabetes Mellitus Type Companies in our database. You can also find out about relevant NN1250 insulin detemir Diabetes Mellitus Type Drugs and Medications on this site too.

Showing "NN1250 insulin detemir Diabetes Mellitus Type" Clinical Trials 1–25 of 11,000+

Extremely Relevant

Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

This trial is conducted in Asia, Europe, Japan and South America. The aim of the trial is to compare NN1250 with insulin detemir, both combined with insulin aspart, in patients with type 1 diabetes.


The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the pharmacodynamic (effect) and pharmacokinetic (exposure of drug) properties of NN1250 in subjects with type 2 diabetes of different race and/or ethnicity.

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

This trial is conducted in Europe and in the United States of America (USA). The aim of the trial is to investigate the efficacy and safety of NN1250 in subjects with type 1 diabetes.


A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes

This trial is conducted in Japan. The aim of this clinical trial is to investigate the effect of NN1250 in Japanese subjects with type 1 diabetes.

Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes

This trial is conducted in Europe. The aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir. You will be treated with either insulin detemir or NPH insulin once or twice daily as basal insulin. Additionally you will receive insulin aspart as bolus insulin

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

This trial is conducted in Europe and North America. The aim of this clinical trial is to compare NN1250 with insulin glargine, as add-on to subject's ongoing treatment with metformin and/or DPP-4 inhibitors, in patients with type 2 diabetes being treated with oral anti-diabetic drugs (OADs).

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 with insulin glargine, as add-on to subject's ongoing treatment with metformin and/or DPP-4 inhibitors, in patients with type 2 diabetes being treated with oral anti-diabetic drugs (OADs) qualifying for intensified treatment.

Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes

This trial is conducted in Africa, Asia, Europe, Oceania, and South America. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir compared to NPH insulin administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight, and insulin antibodies and side effects).

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to compare two NN1250 formulations with each other and with insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes

Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes

This trial is conducted in Asia. The aim of this trial is to evaluate the blood glucose achieved with insulin detemir as add-on to current oral antidiabetic drug (OAD) treatment in subjects with type 2 diabetes.

Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone

This trial is conducted in Japan. The aim of this trial is to investigate the efficacy of insulin detemir on blood glucose control in type 2 diabetes when added to current OHA treatment.

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare NN1250 plus insulin aspart with insulin glargine plus insulin aspart in patients with type 1 diabetes.

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes

This trial will be conducted in Europe and the United States of America (USA). The aim of this clinical trial is to compare NN1250 with insulin glargine in subjects with type 2 diabetes never treated with insulin. All oral anti-diabetic drug (OAD) treatment will be discontinued when trial participant enters the trial with the exception of metformin and DPP-IV inhibitor treatment (only in countries where DPPIV inhibitor treatment is approved for combination treatment together ...

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 in subjects with type 1 diabetes.

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

The aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/mL formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.

Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics

This trial is conducted in Europe. The aim of this clinical trial is to evaluate the hypoglycaemic response (the response to low blood sugar) to NN1250 in subjects with type 1 diabetes. The trial is designed as a two-period, crossover trial where the trial participant is randomised to one of two treatment periods.

Comparison of Insulin Detemir and NPH Insulin Given Once Daily in Ageing Subjects With Type 2 Diabetes

This trial is conducted in Europe. The aim of the trial is to compare insulin detemir once daily to NPH insulin once daily as measured by blood sugar control in ageing subjects with type 2 diabetes naive to previous insulin therapy.

A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

This trial is conducted in Europe. The aim of this clinical trial is to evaluate the effect on the blood glucose-lowering effect of NN1250 in subjects with type 1 diabetes.

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics

This trial is conducted in Europe. The aim of this clinical trial is to compare the blood glucose lowering effect of NN5401 with NN1250 and insulin aspart in subjects with type 1 diabetes.Where the trial participant will receive one single dose of each trial product in varying order.

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

This trial is conducted in Europe, Oceania and in the United States of America (USA). The aim of this clinical trial is to compare the long-term safety of NN5401 plus insulin aspart with insulin detemir plus insulin aspart in type 1 diabetes.

Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea

This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type 2 diabetes mellitus in Korea.

Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes

This trial is conducted in Europe. The purpose of this trial is to investigate if there is any change in the mechanism of energy expenditure (i.e. the way in which energy is used) in patients with type 1 diabetes, whilst taking two different, commercially available insulins for the treatment of their diabetes.

Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes

Patients with diabetes treated with insulin often gain weight, which may deter patients from adhering to insulin treatment. Detemir is one type of long acting insulin approved by the Food and Drug Administration for use in people with diabetes. It is similar to other long acting insulins (NPH, glargine) except that it has been associated with less weight gain compared to other types of insulin. The reasons for this are still unclear. One possibility is that detemir insulin ac...

Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

To determine whether use of detemir compared to neutral protamine hagedron (NPH) decreases rates of composite neonatal outcome and maternal hypoglycemia events in women with Type 2 Diabetes Mellitus (T2DM).


More From BioPortfolio on "NN1250 insulin detemir Diabetes Mellitus Type"

Advertisement
Quick Search
Advertisement
Advertisement